Published on August 28, 2012 at 8:28 AM
Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the "Company") today announced that a first patient
has been recruited for a Phase 2A trial with its ghrelin agonist,
AEZS-130 in patients with cancer cachexia. The study is conducted under
a Cooperative Research and Development Agreement (CRADA) between
Aeterna Zentaris and the Michael E. DeBakey Veterans Affairs Medical
Center which is funding the study. Cachexia, characterized by
diminished appetite and food intake in cancer patients, is defined as
an involuntary weight loss of at least 5% of the pre-illness body
weight over the previous 6 months. Jose M. Garcia, MD, PhD, Assistant
Professor, Division of Diabetes Endocrinology and Metabolism,
Departments of Medicine, Molecular and Cell Biology, the NCI-designated
Dan L. Duncan Cancer Center and the Huffington Center on Aging at
Baylor College of Medicine and Michael E. DeBakey Veterans Affairs
Medical Center, is acting as the Principal Investigator of this trial
conducted in Houston, Texas.
Juergen Engel, PhD, President and CEO of Aeterna Zentaris stated, "This
is a key study as it allows us to venture into the field of
cancer-cachexia, an indication with high unmet medical needs. Because
cachexia is very common among cancer patients, our oral ghrelin
agonist, AEZS-130, could represent a novel treatment option for many of
the 1.5 million people diagnosed with cancer each year, in the U.S.
SOURCE AETERNA ZENTARIS INC.